Form 4: Galera Therapeutics Acquires Nova Pharmaceuticals in Merger Transaction

Nancy T. Chang, a director and 10% owner of Galera Therapeutics, reports changes in beneficial ownership following the acquisition of Nova Pharmaceuticals.

Summary

• On December 30, 2024, Galera Therapeutics acquired Nova Pharmaceuticals through a merger agreement.
• As part of the merger, a subsidiary of Galera merged with Nova, with Nova surviving as a wholly-owned subsidiary.
• Following the initial merger, Nova will merge into another Galera subsidiary, with that subsidiary being the surviving entity.
• Nancy T. Chang, a reporting person, acquired 1,841.92 shares of Series B Non-Voting Convertible Preferred Stock in exchange for shares of Nova Common Stock.
• The Nova Common Stock was automatically converted into Series B Preferred Stock at an exchange ratio of 177.9117.
• Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock, subject to stockholder approval and certain limitations.
• Stockholder approval for the conversion of Series B Preferred Stock into Common Stock will be sought between twelve and eighteen months after the closing date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document describes a standard merger transaction and the resulting changes in beneficial ownership. The potential for future conversion of preferred stock into common stock could be viewed positively.

Positives

• The acquisition of Nova Pharmaceuticals could bring strategic advantages to Galera Therapeutics.
• The conversion feature of the Series B Preferred Stock offers potential upside for the holder upon stockholder approval.

Risks

• Stockholder approval for the conversion of Series B Preferred Stock is not guaranteed.
• The value of the Series B Preferred Stock is dependent on the future performance and stock price of Galera Therapeutics.

Future Outlook

The Issuer will submit to its stockholders for their consideration the approval of the conversion of the Series B Preferred Stock into shares of Common Stock no earlier than twelve months following the Closing, but no later than eighteen months following the Closing.

Industry Context

The pharmaceutical industry is characterized by frequent mergers and acquisitions as companies seek to expand their product pipelines, acquire new technologies, and achieve economies of scale. This acquisition aligns with that trend.

Stakeholder Impact

• Shareholders of Galera Therapeutics will be impacted by the potential dilution from the conversion of Series B Preferred Stock.
• Employees of Nova Pharmaceuticals will be integrated into Galera Therapeutics.
• The acquisition may impact the competitive landscape for other companies in the pharmaceutical industry.

Next Steps

• Galera Therapeutics will seek stockholder approval for the conversion of Series B Preferred Stock into Common Stock between twelve and eighteen months after the closing date.

Key Dates

Keywords

Merger, Acquisition, Galera Therapeutics, Nova Pharmaceuticals, Series B Preferred Stock, Beneficial Ownership, Form 4, Conversion